Sanofi and Regeneron's Dupixent Approved in the EU as the First Targeted Medicine to Treat Young Children With Chronic Spontaneous Urticaria
April 14, 2026
April 14, 2026
PARIS, France, April 14 -- Sanofi, a life sciences company, issued the following news release:
* * *
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
* Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticari . . .
* * *
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
* Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticari . . .